Harvest Investment Services LLC Invests $236,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Harvest Investment Services LLC acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,707 shares of the company’s stock, valued at approximately $236,000.

A number of other institutional investors also recently added to or reduced their stakes in MIRM. Hsbc Holdings PLC purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $269,000. Tower Research Capital LLC TRC raised its position in Mirum Pharmaceuticals by 260.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,112 shares of the company’s stock worth $211,000 after acquiring an additional 3,694 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Mirum Pharmaceuticals by 6.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,085 shares of the company’s stock valued at $996,000 after acquiring an additional 1,356 shares during the period. Nan Fung Group Holdings Ltd boosted its position in shares of Mirum Pharmaceuticals by 18.1% during the 4th quarter. Nan Fung Group Holdings Ltd now owns 125,330 shares of the company’s stock worth $5,182,000 after purchasing an additional 19,230 shares in the last quarter. Finally, Alpha DNA Investment Management LLC acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth $441,000.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $39.43 on Wednesday. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $54.23. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -19.52 and a beta of 1.00. The stock has a fifty day moving average of $44.76 and a two-hundred day moving average of $43.97. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The firm had revenue of $99.41 million during the quarter, compared to analysts’ expectations of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. HC Wainwright boosted their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $58.20.

Insider Buying and Selling

In related news, COO Peter Radovich sold 3,177 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total value of $152,241.84. Following the completion of the transaction, the chief operating officer now directly owns 29,588 shares in the company, valued at approximately $1,417,856.96. This represents a 9.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 57,606 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the sale, the senior vice president now directly owns 4,841 shares in the company, valued at approximately $214,698.35. The trade was a 92.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 116,473 shares of company stock worth $5,249,134. 22.87% of the stock is owned by insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.